How does a drug for colorectal cancer work?

NOURAN AMIN | September 25, 2019

article image
Colorectal cancer is a fatal and common disease, and treatment decisions are often based on what genes have been mutated in the development of the cancer. This means that certain patients with colorectal cancer may benefit from the chemotherapeutic ‘cetuximab’ while other patients may be unresponsive. However, the mechanism of how cetuximab works in those patients that do respond to treatment remains largely unknown--that is until a recent study published in the journal Science Signaling.

Spotlight

DocMorris

Rethinking the pharmacy, daring to innovate, looking for a dialogue - this recipe for success made DocMorris the most well-known pharmacy brand in Germany and at the same time Europe's largest mail-order pharmacy. Over 4 million customers have now ordered medicines from DocMorris, a subsidiary of Zur Rose AG. Approximately 500 people work on the success of DocMorris with progressive ideas and passion in international teams.

OTHER ARTICLES

Roche Prepares to Launch COVID-19 Antibody Test System

Article | April 17, 2020

Swiss pharma giant Roche is joining the race to develop a test for COVID-19 antibodies in people who have been exposed to the disease. This morning, Roche announced the development and upcoming launch of its Elecsys Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the SARS-CoV-2, the virus that causes COVID-19. Roche is eying May for the launch of the test in Europe and is in talks with the U.S Food and Drug Administration for emergency approval of the system. Antibody testing is central to help identify people who have been infected by the virus, especially those who may have been infected but did not display symptoms, the company said. Roche noted that as more information becomes available about immunity levels to COVID-19, society can return to a sense of normal much more quickly. Roche’s test will join a number of other antibody tests that have recently come on the market. Earlier this month the U.S. Food and Drug Administration approved the first blood test for COVID-19 antibodies.

Read More

Pharmacist eCare Plan - the newest disrupter in health data exchange?

Article | February 25, 2020

Every member of the health care team shares a common goal of optimizing patient outcomes. Yet each specialty and position of the healthcare team has a unique workflow facilitated by various tools, from an operative report to a progress note. In this regard the pharmacist plays a pivotal function in medication management and requires documentation specific to that role. The Pharmacist eCare Plan (PeCP) allows for an interoperable note to be used in the pharmacy to assist in the exchange of patient information, including active medication list, laboratory results, and payer information. To allow for this, a new type of clinical document architecture for the PeCP was created and standardized for use across pharmacies.

Read More

Clinical Development Risks and Issues in a COVID-19 World

Article | March 20, 2020

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).

Read More

Five Ways to Manage Your Trial Effectively in a Fast-Changing Global Environment

Article | March 11, 2020

Over the past half-century, clinical trials have grown increasingly complex. A flood of new data from novel sources combined with more elaborate study designs and tougher regulatory standards have lengthened timelines and hiked costs, contributing to a steady decline of efficiency. It all adds up: Nearly half of all drug launches underperform revenue expectations. And if that isn’t enough, the outbreak of COVID-19 worldwide is having an effect on how life sciences companies operate their businesses, including how clinical trials are conducted. Most clinical trial research organizations have tried to adapt by tweaking a platform here, adding a new app there, but this has only yielded patchwork systems of sites, spreadsheets and dashboards that further burden the process.

Read More

Spotlight

DocMorris

Rethinking the pharmacy, daring to innovate, looking for a dialogue - this recipe for success made DocMorris the most well-known pharmacy brand in Germany and at the same time Europe's largest mail-order pharmacy. Over 4 million customers have now ordered medicines from DocMorris, a subsidiary of Zur Rose AG. Approximately 500 people work on the success of DocMorris with progressive ideas and passion in international teams.

Events